New CDC Guidelines for People who are Immunocompromised  

New CDC Guidelines for People who are Immunocompromised 
The OIF’s Medical Advisory Council recommends following the Centers for Disease Control and Prevention (CDC) COVID-19 guidelines. TheCDC now recommends that people whose immune systems are moderately to severely compromised receive an additional dose of mRNA COVID-19 vaccine after the initial 2 doses. Having OI alone does not make a person immunocompromised. It is important to check with your doctor about receiving a third dose of the mRNA COVID-19 vaccine. Widespread vaccination is a critical tool to help stop the pandemic. Read CDC’s statement.

COVID-19: Delta Variant
The Centers for Disease Control and Prevention states the following in regards to COVID-19 Delta variant transmission rate and severity:
The Delta variant causes more infections and spreads faster than earlier forms of the virus that causes COVID-19. It might cause more severe illness than previous strains in unvaccinated people.

  • Vaccines continue to be highly effective at preventing hospitalization and death, including against this variant.
  • Fully vaccinated people with breakthrough infections from this variant appear to be infectious for a shorter period.
  • Get vaccinated and wear masks indoors in public spaces to reduce the spread of this variant.


COVID -19: Delta Variant and Mask Recommendation
The Centers for Disease Control and Prevention states “To maximize protection from the Delta variant and prevent possibly spreading it to others, wear a mask indoors in public if you are in an area of substantial or high transmission.” (Information from the Centers for Disease Control and Prevention website)

Here at the OIF we are pleased that our second COVID-19 survey results showed that 82% of respondents wear a mask or facial covering all the time when they are in public or indoors and unable to socially distance.

For more information about COVID-19, including the Delta variant, COVID-19 Vaccination Updates and Vaccine Finder resource, please visit the OIF’s COVID-19 toolkit at